Neoplasm, Prostate
6
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Health Gatherings - For Your Health After Cancer
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer
AMG 386 and Abiraterone for Advanced Prostate Cancer
Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer